Regenerative Therapy for Neuropathies
Company Founded Year
Company Number of Employees
NeuroPharmacology | NeuroBioTechnology
Biotechnology & Biopharmaceutical
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Biochemical: pharmacological drugs (Developing drugs)
Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies. The company is currently focused on a treatment for ischemic optic neuropathy.
Regenera will conduct a phase 3 study in the U.S. for evaluating the efficacy and safety of RPh201 treatment in participants diagnosed with NAION. It will also commence a phase 2 study in Canada that will evaluate the safety, tolerability, and clinical benefit of RPh201 in individuals with Alzheimerâ€™s disease, with or without coexisting cerebrovascular disease.
Regenera collaborates with the Henry Ford Health System to investigate the therapeutic effects of RPh201 on stroke recovery in a rat model of embolic middle cerebral artery occlusion (MCAO).